Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals Limited has submitted to BSE and NSE copies of newspaper clippings containing its audited financial results for the quarter and year ended 31st March 2025, as required under Regulation 47 of SEBI (LODR) Regulations, 2015. The results were approved by the Board on 30th May 2025 and published on 31st May 2025 in Free Press (Mumbai and Indore editions) in English and Choutha Sansar in Hindi, along with a QR code linking to the full results. From the published extract: Total Income from Operations fell to Rs. 858.77 lakhs in Q4 FY25 from Rs. 1,560.84 lakhs in Q4 FY24, while full-year FY25 revenue stood at Rs. 3,370.74 lakhs. Net Profit after Tax came in at Rs. 19.96 lakhs for Q4 FY25 (vs Rs. 24.87 lakhs in Q4 FY24) and Rs. 55.78 lakhs for the full year FY25. Basic and Diluted EPS for Q4 FY25 were Rs. 0.12 each. Equity Share Capital stood at Rs. 1,627.38 lakhs, while reserves were negative at Rs. (125.42) lakhs, indicating accumulated losses.
This is a routine compliance filing confirming the public dissemination of already-approved Q4 and FY25 results, so no fresh stock-moving event is triggered. However, the numbers themselves point to a sharp year-on-year decline in quarterly revenue and profitability, and the negative reserves position is a concern that investors should track going forward.